- Home
- PSF vs ANNX Comparison
PSF vs ANNX Comparison
Compare PSF & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- ANNX
- Stock Information
- Founded
- PSF 2010
- ANNX 2011
- Country
- PSF United States
- ANNX United States
- Employees
- PSF N/A
- ANNX N/A
- Industry
- PSF Investment Managers
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- ANNX Health Care
- Exchange
- PSF Nasdaq
- ANNX Nasdaq
- Market Cap
- PSF 236.8M
- ANNX 252.3M
- IPO Year
- PSF N/A
- ANNX 2020
- Fundamental
- Price
- PSF $19.71
- ANNX $2.38
- Analyst Decision
- PSF
- ANNX Strong Buy
- Analyst Count
- PSF 0
- ANNX 4
- Target Price
- PSF N/A
- ANNX $12.50
- AVG Volume (30 Days)
- PSF 25.0K
- ANNX 1.4M
- Earning Date
- PSF 01-01-0001
- ANNX 08-11-2025
- Dividend Yield
- PSF 7.69%
- ANNX N/A
- EPS Growth
- PSF N/A
- ANNX N/A
- EPS
- PSF N/A
- ANNX N/A
- Revenue
- PSF N/A
- ANNX N/A
- Revenue This Year
- PSF N/A
- ANNX N/A
- Revenue Next Year
- PSF N/A
- ANNX N/A
- P/E Ratio
- PSF N/A
- ANNX N/A
- Revenue Growth
- PSF N/A
- ANNX N/A
- 52 Week Low
- PSF $16.00
- ANNX $1.29
- 52 Week High
- PSF $20.19
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- PSF 56.47
- ANNX 54.28
- Support Level
- PSF $19.64
- ANNX $2.26
- Resistance Level
- PSF $19.78
- ANNX $2.81
- Average True Range (ATR)
- PSF 0.11
- ANNX 0.21
- MACD
- PSF -0.01
- ANNX -0.02
- Stochastic Oscillator
- PSF 52.50
- ANNX 45.68
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.